- Home
- TNGX vs IHS Comparison
TNGX vs IHS Comparison
Compare TNGX & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNGX | IHS |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNGX | IHS |
|---|---|---|
| Price | $19.34 | $8.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $18.75 | $8.11 |
| AVG Volume (30 Days) | ★ 3.7M | 2.3M |
| Earning Date | 03-05-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $62,384,000.00 | N/A |
| Revenue This Year | N/A | $3.90 |
| Revenue Next Year | N/A | $2.64 |
| P/E Ratio | ★ N/A | $5.85 |
| Revenue Growth | ★ 48.29 | N/A |
| 52 Week Low | $1.04 | $4.21 |
| 52 Week High | $21.82 | $8.95 |
Technical Indicators
Market Signals| Indicator | TNGX | IHS |
|---|---|---|
| Relative Strength Index (RSI) | 66.38 | 55.35 |
| Support Level | $6.77 | $7.82 |
| Resistance Level | N/A | $8.74 |
| Average True Range (ATR) | 1.12 | 0.10 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 54.44 | 64.62 |
Price Performance
Historical ComparisonAbout TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.